P
atients with clinical stage I and II non-small cell lung cancer (NSCLC) have classically been considered candidates for primary surgery. Surgical treatment alone can cure a substantial portion of these patients, as high as 80% of those with pathologic T1N0 squamous cell carcinomas. 1 Histologic involvement of hilar and/or mediastinal lymph nodes or pathologic T3 status clearly indicates a poorer prognosis, with increased risk of both local and systemic recurrence, and has often been considered an indication for adjuvant postoperative treatment. While effective adjuvant therapy is clearly desirable in this setting, there has been considerable controversy as to whether any currently available therapy given in the postoperative setting is of sufficient clinical benefit to be considered an appropriate standard of care. This article will review data of recent trials, addressing the roles of both locoregional and systemic adjuvant strategies and suggest strategies for future clinical investigations.
Postoperative Adjuvant Therapy: General Considerations
Postoperative adjuvant therapy may be defined as treatment administered to patients who have undergone surgical removal of all known disease, but who are considered at risk for recurrence. This excludes those patients with incomplete resections, microscopically positive margins, intraoperative tumor spill, and other situations where there is known, albeit often microscopic and nonevaluable, residual disease. In the true adjuvant setting, one is treating the individual patient because of the statistical risk that he or she still has disease despite an apparent complete resection. Such reasoning entails the treatment of some individuals who are in fact already cured and stand to gain nothing from adjuvant treatment.
The rationale for adjuvant therapy (using any modality) hinges on four propositions:
1. Many patients who have undergone "curative" resections actually have remaining viable tumor cells, either locally, systemically, or both. 2. This residual microscopic tumor will, if no intervention is taken, grow and, after an interval, lead to clinically detectable disease. 3. Treatment of clinically apparent recurrent disease is rarely curative. Survival of most patients with recurrence is short and of impaired quality. 4. The effectiveness of most currently available anticancer treatments, including radiation therapy and cytotoxic chemotherapy, is inversely related to tumor burden. For any given level of treatment intensity, small amounts of tumor are more likely to be eradicated than larger ones.
The arguments have been validated by the development of effective adjuvant therapy for patients with breast and colorectal cancer, but the effectiveness of adjuvant therapy has remained controversial in other common human tumors, such as squamous cell carcinomas of the head and neck and NSCLC.
Rates and Patterns of Failure Following Surgical Resection
Several investigators and cooperative groups have published careful studies of the follow-up of resected patients that allow us to distinguish groups of patients at risk for local and/or systemic failure following primary surgical resection. Several of these series are summarized in Tables  1, 2 . It can be seen that both local and distant relapse rates increase with increasing T and N stages, and that distant failure is more common than local failure (either alone or as a component) for all stage groups. Patterns of failure vary to some degree with histologic type, with adenocarcinomas and large cell undifferentiated carcinomas more likely to spread distantly than squamous cell carcinomas. Local failure, however, contributes a substantial portion of the overall failure risk for patients with N2 nodal involvement.
Several more recent series have attempted to determine in further detail the effect of the extent of nodal involvement on local control and survival. Sawyer et al 8 reported data on several hundred patients resected at the Mayo Clinic. On univariate analysis, they found that both the number of involved N2 nodal stations (single vs multiple) and involved N2 nodes (single vs multiple) correlated with 4-year survival, although neither correlated significantly with local control. On multivariate analysis, however, the extent of N2 nodal involvement was no longer significantly correlated with either of these outcomes, while the number of involved N1 nodes was highly predictive of both local control and survival. Patients with involvement of only inferior mediastinal nodes had better survival than those with inferior and superior mediastinal involvement, although this did not predict for local control. The authors noted that the lack of correlation of extent of N2 involvement on multivariate analysis may have been due in part to the fact that complete nodal dissections or extensive samplings were not generally performed, with dissection terminated with the finding of any degree of N2 involvement.
Andre et al 8a described 702 patients with resected N2 disease and found that two factors were highly predictive of survival. These included whether N2 involvement was detected clinically by CT scan in patients with minimal N2 disease (ie, in nodes Ͻ 1 cm), and the number of involved N2 levels (single vs multiple). They did not report in detail on patterns of relapse, but noted that local or regional relapses were seen in 26% of patients. CNS relapses were observed frequently in patients with adenocarcinoma or in those who received neoadjuvant chemotherapy (50% and 49%, respectively).
The significance of extracapsular extension (ECE) in lung cancer is not well defined. In squamous cell carcinoma of the head and neck, ECE is highly predictive for local recurrence, while it is not highly predictive in adenocarcinoma of the breast. 9 Unfortunately, the presence or absence of ECE is not routinely reported by most pathologists, and even in the recent North American Intergroup (INT 0115) trial, which required reporting of ECE, this information was not consistently reported (H. Wagner, MD, and L. Martin; personal communication; 1999). One surgical review indicated a poorer prognosis for patients with ECE than intranodal disease, but this has not been well studied in the context of adjuvant mediastinal irradiation. 10, 11 Postoperative Radiation Therapy Several older retrospective series claimed that postoperative irradiation of mediastinal and hilar nodes improved survival in patients with resected NSCLC, particularly if they had nodal metastases. 12, 13 This issue has been investigated in several prospective trials that, although methodologically flawed, provide a consensus answer that overall survival is minimally (if at all) improved, but local failure is probably reduced with such treatment.
The North American Lung Cancer Study Group (LCSG) conducted a phase III trial in which patients with resected squamous cell carcinoma of the lung were randomized between observation and mediastinal irradiation (50 Gy in 5 weeks). 14 Entry was restricted to patients with squamous histology because of the greater tendency of this histology to fail locally rather than distantly, compared with adenocarcinoma and large cell carcinoma. Even for patients with squamous histology, however, distant failure was the most common path of failure after an apparent complete resection (Tables 1, 2 ). The majority of patients had N1 disease, but smaller proportions had N2 or T3N0 disease. The results of the trial were striking. Local failure as a first site of relapse was seen in 20% of patients on the observation arm, but in only 1% of those randomized to adjuvant nodal irradiation. Survival, however, was not significantly improved in the study, either overall or for any subgroup of patients. The LCSG and other trials of adjuvant postoperative radiation have been criticized for their small sample size, mixture of N1 and N2 patients, variable compliance with the assigned treatment regimen, and incomplete patient follow-up by relying on data on site of first failure. It should be remembered, however, that these deficiencies did not prevent the demonstration of a striking effect of radiation therapy (RT) on local control. What was lacking was not the efficacy of the treatment modality in achieving local control, but rather the sufficiency of local control alone for long-term freedom from disease. The Medical Research Council conducted a randomized comparison of observation vs postoperative RT in 308 patients with resected T1-2N1-2 disease. 15 The dose was 40 Gy over 3 weeks, and posterior blocks were allowed to limit the spinal cord dose to 35 Gy. No overall survival difference was seen between the two arms, but there was a suggestion of benefit for patients with N2 disease (3-year survival of 21% in the control arm and 36% with RT). Local recurrence was only moderately reduced, from 41 to 29%, with the RT technique used in this study.
Dautzenberg et al 16 recently reported the results of a large multi-institution randomized trial of postoperative RT conducted by the French Lung Cancer Study and Treatment Group (Groupe d'Etude et de Traitement des Cancers Bronchiques). Patients with complete resection were randomized to observation or postoperative RT to the ipsilateral hilum, mediastinum, and supraclavicular areas. Dose was 40 Gy to the initial fields and an additional 20 Gy to the hilum, bronchial stump, and mediastinum. Treatment was given with four fractions of 2.5 Gy/wk or five fractions of 2.0 Gy/wk, according to local institutional preference. Initially, the trial was limited to a small number of centers and had rigorous requirements for treatment and patient follow-up. Because of poor accrual, the study was opened to a larger number of institutions and data collection requirements were relaxed.
Thirty percent of entered patients were in stage I, 25% in stage II, and 45% in stage III. Overall survival, which was the primary end point of the trial, was significantly decreased for the patients receiving postoperative RT (p ϭ 0.002). There was no difference in cancer-related deaths, but a significant excess of intercurrent deaths was associated with RT (72 vs 24 in the control arm, p ϭ 0.0001). Furthermore, postoperative RT as delivered in this trial failed to significantly improve local disease control, although the difference approached significance for patients with N2 disease. When the excess complications in the RT arm were examined, they were found to correlate with the radiation fraction size but not with total dose.
In an editorial discussing this trial, Bonner 17 pointed out that its design predicted its outcome. The use of high radiation doses, in some cases with larger than usual fractions, for a mixed group of patients, many of whom were at low risk for local failure, would not be likely to produce major clinical benefit.
Several other smaller trials have been reported, and their results are summarized in Table 3 . A common theme of these earlier trials is that while postoperative mediastinal radiation reduces the rate of local failure, this has not translated to improved survival. Several factors, both biological and technical, are likely to contribute to this observation. A survival benefit for postoperative RT would most readily be seen in those patients with frequent rates of local failure and relatively less distant failure. As seen in Tables 1, 2 , this would exclude N0 patients and suggest that N2 patients, particularly those with squamous histology, might show the greatest benefit. The availability of active systemic adjuvant therapy would modify these considerations.
The technical component comes with the ability to appropriately restrict the radiation dose to the appropriate targets and minimize dose to the lungs and heart. This is critical for the limitation of late treatment-related morbidity and mortality in these patients whose smoking has already left them with considerable cardiopulmonary compromise. Two groups have reported data suggesting that the introduction of more modern treatment planning and delivery techniques can reduce either observed morbidity and mortality 26 or reduce calculated normal tissue dose and complication probability 27 in patients receiving adjuvant mediastinal postoperative RT. Such a reduction in the risk of complications might well shift the therapeutic ratio in favor of postoperative RT, but this currently remains a hypothesis to be tested.
In 1998, the Postoperative Radiation Therapy (PORT) Meta-Analysis Trialists Group published a meta-analysis, based on individual data on 22,128 patients from nine randomized trials comparing observation to postoperative RT in NSCLC. 28 They found an overall worsening of survival with radiotherapy, with a 21% relative increase in the hazard ratio, which was highly significant (Fig 1) . However, when the hazard function was examined as a function either of stage (I to III) or nodal status (N0 to N2), it was clear that the excess risk of death was inversely correlated with stage and nodal involvement, highest for stage I and N0 patients and no different from unity for stage III or N2 patients (Fig 2) . They concluded that postoperative RT was detrimental to patients with earlystage (I-II) completely resected NSCLC, but that its role in patients with resected N2 disease remained unclear.
The design of this meta-analysis raises a number of The Cancer and Leukemia Group B (CALGB) is currently conducting a prospective trial of postoperative RT in patients with resected N2 NSCLC (CALGB 9734). All patients receive four cycles of adjuvant carboplatin plus paclitaxel, and are then randomized to no further therapy or to RT to the mediastinum (50 Gy in 25 fractions). While this study addresses the important issue of the role of postoperative RT in N2 patients, it has several possible methodologic problems. First, based on current data, it is difficult to justify adjuvant chemotherapy with this regimen as proven standard therapy. Second, there are few data on the efficacy of delayed postoperative RT in improving local control. Unless the chemotherapy is effective in at least suppressing proliferation of residual microscopic mediastinal disease, the 12-week delay in starting RT may reduce its efficacy, as has been reported in other tumor sites, such as breast and head and neck. In this trial, it will be necessary first to determine whether delayed mediastinal irradiation improves local control, and then, only if it does, ask further whether this impacts survival.
Postoperative Chemotherapy
The high rates of systemic failure following resection of NSCLC have long made the development of effective systemic therapy a high priority in lung cancer. Unfortunately, despite the great need for such treatment and the frequency of lung cancer, clinical trials of postoperative adjuvant chemotherapy have been few and often small, particularly when compared to trials in other diseases, such as breast cancer.
Several reviews have summarized the state of the art of adjuvant chemotherapy in resected NSCLC, including both completed trials and those currently underway. 29 -31 The authors have observed that, while there have been hints of biological activity of adjuvant postoperative chemotherapy, there has not been a consistent effect from trial to trial, either for stage I patients or for those with nodal metastases. Tables 4, 5 summarize results of the larger trials. Because of this lack of consensus, the NSCLC Meta-analysis Group conducted a meta-analysis of all published randomized trials comparing observation with adjuvant chemotherapy. Although there was no overall benefit seen, the results were distinctly different by type of chemotherapy regimen. Older alkylating agent-based regimens worsened survival by 5%, whereas cisplatin-based regimens gave a 5-year survival improvement of 5% (Table 6 ). While there was considerable heterogeneity of stage, surgical procedure, and planned as well as delivered chemotherapy, this result suggested modestly active chemotherapy for metastatic disease could improve survival in the adjuvant setting, as had been previously demonstrated in breast and colorectal cancers. It was believed that differences between the older and newer drug regimens likely reflected both greater intrinsic activity of the newer drugs, as well as improved ability to deliver adequate dose-time schedules because of aggressive and effective supportive care (eg, better antiemetics, improved management of neutropenia).
In the late 1980s, the clinical cooperative groups in the United States and Canada planned and activated a large intergroup trial designed to test the efficacy of postoperative chemotherapy in patients with completely resected N1 and N2 NSCLC. After extensive discussion of trial design, a two-arm comparison of postoperative RT with or without concurrent chemotherapy (cisplatin and etoposide) was adopted. The use of postoperative RT in both arms was designed to optimize local control, potentially increasing the ability to detect an effect of chemotherapy on systemic metastases. It was also believed that a comparison of two treatment arms rather than treatment vs observation would be more acceptable to both patients and physicians. Four hundred eighty-eight patients were entered on this trial, and 368 were found to be fully eligible and evaluable. The difference between these two numbers largely reflects the number of patients who did not have adequate nodal sampling or dissection as specified by the protocol. Specifically, patients were excluded if they had been registered as N1 without having had adequate sampling of mediastinal nodes.
The results of this trial, INT 0115 (E3590), were first presented at the annual meeting of the American Society of Clinical Oncology in 1999. 41 There was no difference in survival for the two arms (Fig 3) . This conclusion held regardless of whether all 488 entered patients or 368 eligible and evaluable patients were considered. Multivariate analysis does not show a benefit of the chemotherapy used in this study (four cycles of cisplatin and etoposide beginning concurrently with the start of radiotherapy) for any clinical subset of patients. Concurrent chemoradiation therapy also failed to improve local mediastinal control, compared to radiotherapy alone. Overall, it was not possible to show any benefit for adjuvant chemoradiation as delivered in this study.
While much of the variability in recent adjuvant trials is probably due to the statistical noise inherent in small studies, there may also be valid biological differences in molecular alterations of specific tumors. In a trial where there was an overall benefit from adjuvant tegafur, Takada et al 42 demonstrated that there was also significant improvement for patients with normal p53 function as assessed by immunohistochemistry (Table 7) . Similarly, in the INT 0115 trial, Schiller et al 43 examined the impact of p53 and ras mutations in predicting effectiveness of adjuvant treatment with postoperative RT and cisplatin/ etoposide to postoperative RT without chemotherapy. They found that p53 status did not correlate with impact of therapy, but that recurrence was significantly reduced for patients with wild-type but not mutant K-ras (Table 8 ). In the future, it may be that these and other predictive markers can be used to select individualized adjuvant 43 TRT ϭ thoracic radiation therapy; PE ϭ cisplatin, etoposide; WT ϭ wild type; MUT ϭ mutation; see Table 4 for other abbreviation. 
CNS Relapse and Its Prevention
It has long been recognized that the CNS, chiefly the brain, is a common metastatic site in NSCLC. This is particularly true for adenocarcinoma and large cell undifferentiated carcinoma. In small cell lung cancer (SCLC), where the risk of CNS metastases has long been recognized, a number of trials and a recent meta-analysis have shown that prophylactic brain irradiation (PCI) administered to patients in complete remission following induction therapy can significantly reduce the risk of brain metastases (by about 50%), as well as produce a modest but significant improvement in overall survival (5.4% at 3 years). 44 While the global risk for brain metastases, particularly isolated brain metastases, was modest in a review of mostly early stage patients treated on several LCSG trials, 45 several recent trials, which have used aggressive neoadjuvant therapy plus resection, have shown much higher rates, ranging from 30 to 40% (Table 9 ). This suggests that prophylactic management of brain relapse, if effective and nontoxic, might improve quality of life and possibly survival in NSCLC.
Stuschke et al 48 recently reported a retrospective comparison of patients on their neoadjuvant trial who did or did not receive PCI. Patients had N2 disease and were treated with induction cisplatin/etoposide for three cycles followed by concurrent accelerated RT (45 Gy/30 fractions for 3 weeks) during the fourth chemotherapy cycle. Responding patients then underwent resection. Because of a high rate of CNS failure seen in the first 28 patients, subsequent patients received PCI (30 Gy/15 fractions) at the same time as chest irradiation. PCI reduced the rate of isolated brain relapse as first site of failure from 30 Ϯ 10% to 8 Ϯ 6% at 4 years, and decreased the overall incidence of brain metastases from 54 Ϯ 10% to 13 Ϯ 6%. Both squamous and nonsquamous histology patients were at risk for brain metastases without PCI and had reduction with PCI.
Several small randomized trials of PCI in patients with NSCLC have been published (Table 10) . In these trials, the status of intrathoracic disease was not specified and there was likely uncontrolled disease in the majority. Although differences in brain relapse rate did not reach statistical significance in any of these trials, all showed a trend to a lower rate with PCI.
It has been noted for several decades that long-term survivors of SCLC, particularly those who have received PCI, may have a variety of neurologic abnormalities. The frequency of these has varied tremendously from series to series, in part due to the end point being reported (significant impairment in everyday activities, abnormalities of detailed neuropsychiatric testing, or asymptomatic changes on CT and/or MRI), as well as due to differences in radiation dose, schedule, and timing relative to chemotherapy. In some series, the rate of significant impairment has been substantial. The etiology of these effects is poorly understood. Several studies have reported differences in pre-PCI neurologic functioning between SCLC patients and age-and gender-matched control subjects. 52, 53 More recent randomized trials evaluating PCI in SCLC complete responders suggest less neurologic impairment than observed in some earlier trials, perhaps related to more carefully fractionated radiotherapy, shorter overall duration of chemotherapy, and avoidance of concurrent chemotherapy and PCI. However, the number of patients at risk for late neurotoxicity in these recent trials is low, and further careful follow-up is required.
These data strongly suggest that the time has come for a prospective trial of PCI in patients with NSCLC at high risk for isolated CNS relapse, most likely those with resected N2 disease
Conclusion
The role of adjuvant RT for patients with resected early stage NSCLC remains ill-defined. Several prospective trials have indicated that mediastinal RT can substantially decrease local relapse rates, particularly for patients with squamous histology, but that this does not lead to a measurable improvement in survival. The recent metaanalysis as well as the large randomized trial reported by Dautzenberg et al 38 have suggested significant survival detriment for adjuvant mediastinal RT, particularly for patients with N0 or N1 disease. As discussed above, these series must be interpreted carefully in light of the substantial heterogeneity in surgical and radiotherapeutic technique. With excessively toxic RT applied to N0 patients who are at low risk of local recurrence, a survival detriment is not surprising. It remains to be determined whether postoperative RT given with modern treatment planning techniques is of benefit for patients with N2 disease. The current CALGB trial may answer this question. Unfortunately, no other prospective trials of postoperative radiotherapy are presently underway.
While a modest survival gain might not have been detectable in the small trials conducted to date, it is likely that the high frequency of systemic disease in patients with positive nodes mandates effective systemic as well as local adjuvant strategies. In patients with high risk of local failure (multiple positive nodes, extracapsular disease, known incomplete resection), it is reasonable to offer postoperative RT. Whether combinations of adjuvant RT and chemotherapy will lead to improved survival in these patients remains to be studied. While adjuvant mediastinal irradiation has often been viewed as a routine and standard technique, it can be associated with significant cardiac and pulmonary toxicity, and care in treatment planning and delivery is mandated as much here as in definitive treatment. Despite the compelling rationale for adjuvant systemic therapy in patients with resected node-positive NSCLC, it has been difficult to identify an effective regimen with present agents. While a meta-analysis of Ͼ 1,000 patients showed a survival benefit of about 5% using cisplatincontaining regimens, this was not confirmed in the large INT 0115 trial examining postoperative RT with or without cisplatin and etoposide. This and other discrepancies between published series clearly point to the need for further prospective trials that include a control arm with no postoperative adjuvant therapy. However, recent data from several series indicating greater benefit for preoperative chemotherapy make this the treatment sequence of choice in patients who can be identified as high risk when treated with surgery alone.
In patients with locally advanced NSCLC, the incidence of brain metastases is high, and has increased as local and systemic therapies have improved. With CNS failure approaching 50% in patients with resected stage IIIA (N2) in several series, and the limited effectiveness of treatment for established brain metastases, the role of PCI in patients with locally advanced NSCLC who have responded well to initial treatment (good response to chemotherapy and/or radiotherapy, complete surgical resection) needs to be investigated prospectively. Our experience with investigation of PCI in SCLC suggests that these trials should be large enough to detect a modest but clinically meaningful improvement in survival (on the order of 5%), and should look carefully at both baseline and post-PCI neurologic functioning.
Finally, it must be kept in mind that even those patients with the most favorable NSCLC, those with resected T1N0M0 lesions, are at high risk for developing second primary lung cancers, on the order of 2 to 3%/yr for at least 10 years after initial resection. 54 This high-risk group represents an ideal cohort for the investigation of new radiographic, immunologic, and molecular technologies for early detection of second primary tumors. 55 
